About: Reduced Incretin Effect in Type 2 Diabetes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Reduced Incretin Effect in Type 2 Diabetes Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Filip K. Knop et al published 18 May 2007 in Diabetes

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2007 (uk) article scientifique publié en 2007 (fr) im Mai 2007 veröffentlichter wissenschaftlicher Artikel (de) article by Filip K. Knop et al published 18 May 2007 in Diabetes (en)
publication date	wds:Q58168459-01E0F5F4-C4CD-48FC-81F8-52BC2939022A
publication date	2007-05-18 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58168459-4CDB6DC6-19AF-4832-8645-4D2BAE3A3969
language of work or name	English
author name string	wds:Q58168459-6B50999C-91D1-49BE-98B0-F756C652C1D7 wds:Q58168459-B23797A1-2555-472E-A286-0CB49D953426
author name string	Steen Larsen Thure Krarup
rdfs:label	Reduced Incretin Effect in Type 2 Diabetes (en) Reduced Incretin Effect in Type 2 Diabetes (nl)
skos:prefLabel	Reduced Incretin Effect in Type 2 Diabetes (en) Reduced Incretin Effect in Type 2 Diabetes (nl)
name	Reduced Incretin Effect in Type 2 Diabetes (en) Reduced Incretin Effect in Type 2 Diabetes (nl)
author	wds:Q58168459-076DA238-3410-4FDB-B51E-42A11051FF72 wds:Q58168459-690984A3-CBAD-4714-B939-5ED5AE3BF290 wds:Q58168459-7CCBBEF9-D454-4F61-A579-1CE581983B95 wds:Q58168459-85D2A583-9A6B-4A14-A0C0-522DBDDD1C0B wds:Q58168459-C49E1FD2-50A9-4749-B887-9D7077B3BD43 wds:Q58168459-CF40D946-720F-4C04-BC99-3392F4F16246
author	Jens Juul Holst Filip K Knop Sten Madsbad Tina Vilsbøll Aage Vølund Patricia M V Højberg
title	wds:Q58168459-9B5538D7-C099-4744-86A1-4FC1CC774218
title	Reduced Incretin Effect in Type 2 Diabetes (en)
page(s)	wds:Q58168459-B1014427-29AA-4D93-BD18-8EC167E4368C
page(s)	1951-1959
instance of	wds:Q58168459-93835F33-0CD6-4210-8A0E-1A7765F4B8C5
instance of	scholarly article
main subject	wds:Q58168459-B17DE180-47D4-483C-BB6A-64FFF4F61E9A
main subject	type 2 diabetes
PubMed ID	wds:Q58168459-93316646-A707-4E41-BBA4-33D136D84B14
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17513701
PubMed ID	17513701
published in	wds:Q58168459-DCD4A219-FA1C-4981-AB1C-C7949DA99696
published in	Diabetes
issue	wds:Q58168459-752DAFD9-1245-43D5-BA84-CFA7FCD04FDE
volume	wds:Q58168459-220843E7-A725-4FE5-B498-A31BDFB621FB
issue	8
volume	56
number of pages	wds:Q58168459-290F7A2B-4F54-4DDA-9FBE-B0EC4C9CE507
number of pages	9 (xsd:decimal)
DOI	wds:Q58168459-D112EBCC-8387-4041-A0D0-B6DBB9FA5F9D
DOI	http://dx.doi.org/10.2337/DB07-0100
DOI	10.2337/DB07-0100
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58168459
is cites work of	Incretin responses to oral glucose load in Japanese non-obese healthy subjects Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Glucagon antagonism as a potential therapeutic target in type 2 diabetes Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion Physiology of incretins in health and disease Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties The environment within: how gut microbiota may influence metabolism and body composition Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Regulation of glucagon secretion by incretins The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. The role of incretins in glucose homeostasis and diabetes treatment Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic β-cells via protein kinase A Nutrient-driven incretin secretion into intestinal lymph is different between diabetic Goto-Kakizaki rats and Wistar rats Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes: pancreatic extracellular matrix ultrastructural abnormalities Treatment of prediabetes Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? The role of incretin therapy at different stages of diabetes Incretin effects on β-cell function, replication, and mass: the human perspective 5'AMP-activated protein kinase activity is increased in adipose tissue of northern elephant seal pups during prolonged fasting-induced insulin resistance Mechanisms of diabetes mellitus-induced bone fragility Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? The incretin effect in critically ill patients: a case-control study Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. A high-protein breakfast induces greater insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with type 2 diabetes WNT signalling is both an inducer and effector of glucagon-like peptide-1 Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission GIP and bariatric surgery Incretin physiology and pathophysiology from an Asian perspective Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Incretin responses to oral glucose and mixed meal tests and changes in fasting glucose levels during 7 years of follow-up: The Hoorn Meal Study. Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software